Limits...
Meta-analysis of the association of HLA-DRB1 with rheumatoid arthritis in Chinese populations.

Yang M, Kuang X, Li J, Pan Y, Tan M, Lu B, Cheng Q, Wu L, Pang G - BMC Musculoskelet Disord (2013)

Bottom Line: Individual studies have reported different results regarding the association of HLA alleles with RA in Chinese populations.It was found that HLA-DRB1*04, *0401, *0404, *0405 and *0410 are risk factors for RA in Chinese populations.ESR, CRP, RF, Anti-CCP are different between the DR4+ and DR4- in RA patients in Chinese populations, while there's no difference for indexes of clinical features.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Dermatology, the third affiliated hospital of Guangxi Medical University, 13 Dancun Road, Nanning 530031, Guangxi, People's Republic of China. 4830380@163.com.

ABSTRACT

Background: Individual studies have reported different results regarding the association of HLA alleles with RA in Chinese populations. This study was performed to systematically summarize results on the association of HLA-DRB1 with rheumatoid arthritis (RA) in China.

Methods: We examined the case-control studies concerned about the relationship between HLA-DRB1 and RA and differences of clinical and laboratory parameters between the HLA-DR4 (DR4)+ and DR4- in RA patients in Chinese populations. Odds ratios (ORs) and weighted mean difference (WMD) with corresponding 95% confidence intervals (CI) was used to describe the relationship.

Results: 22 studies with 1690 cases and 1793 controls were included. Chinese populations with RA had significantly higher frequencies of HLA-DRB1*04, *0401, *0404, *0405 and *0410 than controls (ORDRB1*04 =4.19, 95% CI =3.44-5.11, p<0.00001; ORDRB1*0401 =2.53, 95% CI =1.54-4.16, p=0.0003; ORDRB1*0404 =2.28, 95% CI =1.28-4.06, p=0.005; ORDRB1*0405=3.71, 95% CI =2.52-5.45, p<0.00001; ORDRB1*0410 =2.99, 95% CI =1.25-7.14, p=0.01 respectively). As to laboratory parameters, Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Rheumatoid factor (RF), Anti-cyclic citrullinated peptide antibodies (Anti-CCP ) in patients with DR4+ were higher than patients with DR4- (WMD=0.26, 95% CI =0.15-0.37, p<0.00001; WMD = 0.26, 95% CI =0.12-0.41, p=0.0005; WMD = 0.44, 95% CI =0.23-0.65, p<0.00001; WMD = 0.58, 95% CI =0.24-0.91, p=0.0007 respectively). As to clinical features, there was no difference in duration of morning stiffness, number of swollen joints, number of joint tenderness, X-ray phases and joint function between the DR4+ and DR4- in RA patients.

Conclusions: It was found that HLA-DRB1*04, *0401, *0404, *0405 and *0410 are risk factors for RA in Chinese populations. ESR, CRP, RF, Anti-CCP are different between the DR4+ and DR4- in RA patients in Chinese populations, while there's no difference for indexes of clinical features.

Show MeSH

Related in: MedlinePlus

Selection process for the studies included in the Meta-analysis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4231398&req=5

Figure 1: Selection process for the studies included in the Meta-analysis.

Mentions: With our inclusion criteria, a total of 489 references were retrieved for initial review using search strategies as described. 239 citations were excluded from analysis after the first screening based on abstracts or titles. After exclusion of the articles that did not meet the inclusion criteria, we identified 40 potential studies for detail evaluation. Upon further review, 18 articles were eliminated due to the following reasons: 3 studies overlapped with others; 15 studies didn’t provide sufficient data about HLA-DRB1 alleles frequency on cases and/or controls or lacked clinical feature or laboratory indexes data to create for meta-analysis. Finally, 22 studies performed on the association of HLA-DRB1 with rheumatoid arthritis in Chinese populations were included and analyzed. Selection process for the studies included in the meta-analysis is summarized in Figure 1. The main features of eligible studies in our meta-analysis are summarized in Tables 1.


Meta-analysis of the association of HLA-DRB1 with rheumatoid arthritis in Chinese populations.

Yang M, Kuang X, Li J, Pan Y, Tan M, Lu B, Cheng Q, Wu L, Pang G - BMC Musculoskelet Disord (2013)

Selection process for the studies included in the Meta-analysis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4231398&req=5

Figure 1: Selection process for the studies included in the Meta-analysis.
Mentions: With our inclusion criteria, a total of 489 references were retrieved for initial review using search strategies as described. 239 citations were excluded from analysis after the first screening based on abstracts or titles. After exclusion of the articles that did not meet the inclusion criteria, we identified 40 potential studies for detail evaluation. Upon further review, 18 articles were eliminated due to the following reasons: 3 studies overlapped with others; 15 studies didn’t provide sufficient data about HLA-DRB1 alleles frequency on cases and/or controls or lacked clinical feature or laboratory indexes data to create for meta-analysis. Finally, 22 studies performed on the association of HLA-DRB1 with rheumatoid arthritis in Chinese populations were included and analyzed. Selection process for the studies included in the meta-analysis is summarized in Figure 1. The main features of eligible studies in our meta-analysis are summarized in Tables 1.

Bottom Line: Individual studies have reported different results regarding the association of HLA alleles with RA in Chinese populations.It was found that HLA-DRB1*04, *0401, *0404, *0405 and *0410 are risk factors for RA in Chinese populations.ESR, CRP, RF, Anti-CCP are different between the DR4+ and DR4- in RA patients in Chinese populations, while there's no difference for indexes of clinical features.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Dermatology, the third affiliated hospital of Guangxi Medical University, 13 Dancun Road, Nanning 530031, Guangxi, People's Republic of China. 4830380@163.com.

ABSTRACT

Background: Individual studies have reported different results regarding the association of HLA alleles with RA in Chinese populations. This study was performed to systematically summarize results on the association of HLA-DRB1 with rheumatoid arthritis (RA) in China.

Methods: We examined the case-control studies concerned about the relationship between HLA-DRB1 and RA and differences of clinical and laboratory parameters between the HLA-DR4 (DR4)+ and DR4- in RA patients in Chinese populations. Odds ratios (ORs) and weighted mean difference (WMD) with corresponding 95% confidence intervals (CI) was used to describe the relationship.

Results: 22 studies with 1690 cases and 1793 controls were included. Chinese populations with RA had significantly higher frequencies of HLA-DRB1*04, *0401, *0404, *0405 and *0410 than controls (ORDRB1*04 =4.19, 95% CI =3.44-5.11, p<0.00001; ORDRB1*0401 =2.53, 95% CI =1.54-4.16, p=0.0003; ORDRB1*0404 =2.28, 95% CI =1.28-4.06, p=0.005; ORDRB1*0405=3.71, 95% CI =2.52-5.45, p<0.00001; ORDRB1*0410 =2.99, 95% CI =1.25-7.14, p=0.01 respectively). As to laboratory parameters, Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Rheumatoid factor (RF), Anti-cyclic citrullinated peptide antibodies (Anti-CCP ) in patients with DR4+ were higher than patients with DR4- (WMD=0.26, 95% CI =0.15-0.37, p<0.00001; WMD = 0.26, 95% CI =0.12-0.41, p=0.0005; WMD = 0.44, 95% CI =0.23-0.65, p<0.00001; WMD = 0.58, 95% CI =0.24-0.91, p=0.0007 respectively). As to clinical features, there was no difference in duration of morning stiffness, number of swollen joints, number of joint tenderness, X-ray phases and joint function between the DR4+ and DR4- in RA patients.

Conclusions: It was found that HLA-DRB1*04, *0401, *0404, *0405 and *0410 are risk factors for RA in Chinese populations. ESR, CRP, RF, Anti-CCP are different between the DR4+ and DR4- in RA patients in Chinese populations, while there's no difference for indexes of clinical features.

Show MeSH
Related in: MedlinePlus